---
title: KPV Tripeptide
aliases:
  - Lys-Pro-Val
  - Alpha-MSH C-terminal
  - KPV peptide
related:
  - nlrp3-inflammasome
  - bhb-ketones
  - gout
  - peptide-therapy
  - gut-inflammation
sources:
  - peptide-gout-addendum.md
  - nlrp3-exploit-map.md
  - gout-deep-dive.md
---

# KPV Tripeptide (Lys-Pro-Val)

**KPV** is a three-amino-acid peptide derived from the C-terminal fragment (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). It represents the strongest mechanistic case for peptide-based gout management among all known research peptides.

## Mechanism of Action

KPV operates through **dual-pathway inhibition** of the NLRP3 inflammasome cascade, targeting both the priming and activation phases of gout flares:

### 1. NF-κB Inhibition (Signal 1 / Chokepoint 1)

KPV stabilizes IκB-α — the protein that sequesters NF-κB in the cytoplasm — preventing NF-κB nuclear translocation. This blocks the transcription of pro-inflammatory genes including pro-IL-1β and NLRP3 itself. Mechanistically, KPV operates through PepT1-mediated uptake, a distinct pathway from full-length α-MSH that avoids melanocortin receptor activation with its associated side effects.

**(Source: peptide-gout-addendum.md, nlrp3-exploit-map.md)** — "KPV (Lys-Pro-Val) is the active anti-inflammatory fragment of alpha-melanocyte-stimulating hormone (α-MSH). Most of the anti-inflammatory activity of full-length α-MSH can be attributed to this three-amino-acid fragment."

### 2. NLRP3 Inflammasome Inhibition (Signal 2 / Chokepoint 2)

Beyond NF-κB suppression, KPV directly inhibits NLRP3 inflammasome assembly in immune cells — blocking the formation of the protein complex that activates caspase-1. This dual mechanism (both priming suppression AND inflammasome inhibition) mirrors the combined strategy of colchicine + IL-1 blockers, but in a single small molecule.

**(Source: peptide-gout-addendum.md)** — "KPV has been shown to directly inhibit NLRP3 inflammasome activation in immune cells. This means it's not just reducing the fuel (pro-IL-1β) — it's interfering with the ignition system itself."

## Significance for Gout

### Direct NLRP3-MSU Connection

Research has shown that α-MSH and its derivative (CKPV)₂ can **reverse the inflammatory effect of urate crystal formation specifically**. This is not generic anti-inflammatory activity — it is targeted anti-inflammation against the exact trigger (monosodium urate crystals) that drives gout flares.

**(Source: nlrp3-exploit-map.md)** — "Critically for gout: research shows α-MSH and its derivative (CKPV)₂ can reverse the inflammatory effect of urate crystal formation specifically. This isn't a general anti-inflammatory — it's been tested against the exact trigger you're dealing with."

## Gut Anti-Inflammatory Effects

### Intestinal Barrier Healing

KPV demonstrates significant anti-inflammatory properties in the gut. In animal models of DSS-induced and TNBS-induced colitis, orally administered KPV:
- Reduced intestinal inflammation markers
- Decreased colonic myeloperoxidase activity
- Reduced pro-inflammatory cytokine mRNA levels

### PepT1 Transporter Uptake

KPV enters intestinal epithelial cells and immune cells via the PepT1 transporter — the same peptide transporter that handles dietary di- and tripeptides. This gives it direct access to the gut immune system and allows oral administration to reach target tissues.

**(Source: peptide-gout-addendum.md)** — "KPV enters intestinal epithelial cells and immune cells via the PepT1 transporter — the same peptide transporter that handles dietary di- and tripeptides. This gives it direct access to the gut immune system."

### Connection to Uric Acid Excretion

Approximately one-third of uric acid excretion happens through the gut. If KPV reduces intestinal inflammation and supports a healthier gut environment, it could improve conditions for intestinal uricolysis — the gut's contribution to uric acid elimination.

## Evidence Level

**Current status: Preclinical + Mechanistic**

- Cell culture studies: ✓ Confirmed NF-κB and NLRP3 inhibition in immune cells
- Animal models: ✓ Demonstrated gut anti-inflammatory effects in colitis models
- Gout-specific studies: ✗ None published
- Human clinical trials: ✗ None for any indication

**(Source: peptide-gout-addendum.md)** — "Zero peptides on this list have been tested in a human clinical trial for gout. All claims are based on animal models and mechanistic extrapolation from shared inflammatory pathways."

However, the pharmaceutical industry's validation of the target is notable: dapansutrile (direct NLRP3 inhibitor) and firsekibart (anti-IL-1β antibody) are both in Phase 3 trials specifically for gout, suggesting the NLRP3 inflammasome is indeed the correct target.

## Comparison to Other Peptides

| Peptide | Primary Mechanism | Best For |
|---------|-------------------|----------|
| **KPV** | NLRP3 + NF-κB dual inhibition | **Gout flare prevention** |
| BPC-157 | NO system modulation, tissue repair, gut healing | Tissue repair, chronic damage |
| TB-500 | NF-κB inhibition, cell migration, anti-fibrotic | Tissue repair after gout damage |
| GHK-Cu | Gene expression modulation, ECM repair | Long-term joint protection |

**(Source: peptide-gout-addendum.md)** — "Arguably, yes. BPC-157 is a broad-spectrum tissue repair compound that happens to have anti-inflammatory properties. KPV is a *targeted anti-inflammatory* that hits the exact pathways driving gout flares (NLRP3 + NF-κB) and also has gut anti-inflammatory effects relevant to uric acid excretion."

## Delivery Routes

| Route | Bioavailability | Application |
|-------|-----------------|-------------|
| **Subcutaneous injection** | >80% | Systemic NLRP3 suppression for flare prevention |
| **Oral** | Low but sufficient | Gut-targeted anti-inflammatory + intestinal uricolysis support |
| **Sublingual** | ~30-50% | Direct entry to systemic circulation |

**(Source: peptide-gout-addendum.md)** — "KPV is typically administered orally (for gut effects) or subcutaneously (for systemic anti-inflammatory effects). Its small size (just 3 amino acids) gives it an advantage over larger peptides for oral absorption — it's transported by PepT1 and is resistant to significant enzymatic degradation."

### Engineered-koji delivery: format constraint

If KPV is ever co-expressed in an engineered koji strain (Phase 2+ multi-payload track), the **shio-koji format is structurally unsuitable** — KPV is a tripeptide and shio-koji's 7–14 day active-protease environment will hydrolyze exposed peptide bonds. Use dried koji powder (heat-inactivated proteases) or amazake (cooked, brief enzyme exposure) as the carrier instead. See the format-constraint table in [`engineered-koji-protocol.md` §15](./engineered-koji-protocol.md#15-carnosine-co-expression-module) for the full ranking and the underlying biochemistry; the same logic that rules out shio-koji for carnosine rules it out for KPV.

## Connection to SIBO and Lynn

The [[sibo|Small Intestinal Bacterial Overgrowth]] connection is particularly relevant: SIBO drives the same NLRP3 inflammasome pathway that drives gout. KPV's gut anti-inflammatory properties could theoretically benefit both Brian's gout (through NLRP3 suppression and urate excretion support) and Lynn's digestive insufficiency (through reduction of SIBO-related inflammation).

**(Source: peptide-gout-addendum.md)** — "KPV's gut anti-inflammatory properties are especially relevant beyond gout. The same NLRP3 inflammasome pathway that drives gout flares is a central driver of intestinal inflammation — including the chronic low-grade inflammation associated with SIBO."

## Contraindications, Drug Interactions, and Dose-Dependent Risk

> **Standardized safety profile (source: supplements-stack.md, 2026-04-26):** The following section consolidates contraindications, drug interactions, and dose-dependent risk from the supplements catalog.

**Dosing range:** 200–500 mcg/day intranasal (nasal mucosa, high PepT1 expression). Combine timing with BPC-157 spray for convenience.

**Contraindications:**
- Active or recent melanoma (theoretical, based on α-MSH/MC1R signaling — not clinically demonstrated at intranasal doses listed)
- Pregnancy (insufficient data)
- Pediatric use (insufficient data)
- Sourcing-quality unknowns: research peptide suppliers vary widely in purity and endotoxin load

**Drug interactions:**
- **Immunosuppressants (tacrolimus, cyclosporine, biologics):** unstudied; mechanism overlap with NF-κB pathway.
- **Topical/intranasal corticosteroids:** mechanism overlap; no clear pharmacological conflict but redundant signaling.
- No documented small-molecule drug interactions; peptide is rapidly hydrolyzed.

**Dose-dependent risk profile:**
- 200–500 mcg/day intranasal: well-tolerated in published research; main risk is sourcing quality.
- Systemic dosing (subcutaneous, off-label) at multi-mg levels: melanocyte effects (skin darkening) become detectable. Stay intranasal at the doses listed.
- Sourcing: research peptide suppliers without third-party HPLC/MS/endotoxin verification carry product-quality risk that scales with dose and frequency.

**Stack interactions:**
- **Synergy with BPC-157 (non-overlapping pathways):** both small peptides, complementary mechanisms — KPV at NF-κB priming (CP1), BPC-157 at cytoprotection / NO modulation.
- **Mild redundancy with sulforaphane, EGCG, quercetin:** all converge on NF-κB / NLRP3 priming axes; cumulative benefit unclear vs. single-agent.
- **No ABCG2 interaction.** Peptide does not engage transporter axis.

(source: supplements-stack.md)

---

## Practical Considerations

### Dosing & Timing

- **Prophylactic (no flare):** Daily oral + subcutaneous dosing for baseline suppression
- **Prodromal (flare coming):** Increase dose at first sign of joint warmth; sub-Q injection may be most rapid
- **Acute flare:** Peptide is not a replacement for colchicine or NSAIDs; use as adjunct while taking standard flare management
- **Recovery:** Continue KPV to prevent rebound inflammation

### Quality & Supply

KPV is a research peptide without FDA approval. Quality control is critical:
- Source from suppliers providing third-party certificates of analysis (CoA) with HPLC purity data
- Verify mass spectrometry confirmation of peptide identity
- Typical contaminants: bacterial endotoxins (especially problematic for intranasal/subcutaneous routes)

## Related Concepts

- [[nlrp3-inflammasome|NLRP3 Inflammasome]] — The master inflammatory controller in gout
- [[bhb-ketones|Beta-Hydroxybutyrate]] — An endogenous compound hitting 3+ NLRP3 chokepoints
- [[gout|Gout Flare Cascade]] — The full inflammatory pathway KPV targets
- [[sibo|SIBO and Intestinal Inflammation]] — The connection between gut dysbiosis and NLRP3 activation

## Key Insight

**KPV is the peptide most directly targeted to gout's actual mechanism.** While BPC-157 is broader and TB-500 focuses on tissue repair, KPV attacks the exact NLRP3-NF-κB cascade that turns MSU crystals into pain. No other single peptide hits both chokepoints simultaneously. The mechanistic case is strong; the limitation is that **zero human gout trials have been conducted.**

---

*Last updated: April 2026*
*Wiki synthesized from primary research documents*
